“Progesterone should be administered to all women, hysterectomy or not.”
Infertility and Reproductive Medicine Clinics of North America; 1995 Oct;Vol.6(4):653-673.
“Due to the side effects of synthetic progestin’s, natural progesterone is preferred. Progesterone has proven bio-availability and no side effects making it the preferred hormone for menopause.”
American Family Physicians 2000;62: 1339-46.
“Estrogen and progesterone are neuro-protective against cerebral damage. These beneficial effects were blocked by MPA (medroxyprogesterone).”
National Academy Science USA; 2003 Sept. 2;100(8):10506-11.
“Natural estrogen and natural progesterone offer substantial clinical benefit over the synthetic hormones and should be the agents of choice for menopause.”
Obstetrics Gynecology 1989;73:606.
“The estrogen only arm of the WHI Trial demonstrated no increased risk of breast cancer with estrogen. This study therefore demonstrates that the breast cancer increase was due to medroxyprogesterone (Provera?) and not due to estrogen.”
Family Practice News 2004 March 15;1-3.
“Progesterone reduces proliferation of breast cancer cells and induces cellular apoptosis (kills breast cancer cells)”
Maturitas 2003 Dec;46(1):555-58
“Due to the side effects of synthetic progestin’s, natural progesterone is preferred. Progesterone has proven bioavailability and no side effects making it the preferred hormone for menopause.”
American Family Physician 2000; 62:1939-46
“Progesterone raises good HDL cholesterol, whereas MPA (Provera?), lowers good cholesterol. Progesterone increases estrogen beneficial effects whereas MPA reverses estrogen’s benefits. Progesterone has no side effects, whereas MPA has many”
Obstetrics Gynecology 1989;73:606-611.
“Progesterone decreases Breast stimulation 400%, and down regulates breast receptor sites, thereby protecting against breast stimulation.”
Fertility Sterility 1998;69:963-69.
“Mammary tumor stimulation was reduced both by progesterone and Tamoxifen, more so by progesterone by Tamoxifen which is the drug of choice to treat cancer.”
Japan Journal of Cancer Research 1985June;76:699-04.